<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00214786</url>
  </required_header>
  <id_info>
    <org_study_id>003-040</org_study_id>
    <nct_id>NCT00214786</nct_id>
  </id_info>
  <brief_title>Pancreatic Islet Cell Transplantation</brief_title>
  <official_title>Pancreatic Islet Cell Transplantation - A Novel Approach to Immunosuppression and Validation of Remote Site Islet Cell Processing, Islet Cell Culture and Two-Layer Preservation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baylor Health Care System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess a novel approach to immunosuppression in allogenic
      pancreatic islet cell transplant recipients. In addition, the study aims to assess remote
      site islet processing with culture for pancreatic islet cell transplantation in human
      subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to assess a novel approach to immunosuppression in allogenic
      pancreatic islet cell transplant recipients. In addition, the study aims to assess remote
      site islet processing with culture for pancreatic islet cell transplantation in human
      subjects.

      Detailed Description: Diabetes mellitus (DM) type I is a disease that has significant social
      and economical impact. The prevalence of the disease in the United States is about 120,000 in
      individuals aged 19 or less and 300,000 to 500,000 at all ages and 150 million worldwide.

      So far there are no mechanical devices able to effectively adjust the dose of insulin
      injected according to the serum glucose in patients with DM. This leads to less than perfect
      sugar control, with episodes of hypoglycemia. Successful pancreas transplantation averts the
      need of insulin administration.

      The emerging alternative to whole organ pancreas transplantation is pancreatic islet cell
      transplantation (ICT). The process is based on the enzymatic isolation of the pancreatic
      islets from an organ procured from a cadaver donor. The islets obtained are injected into the
      liver in the recipient via percutaneous catheterization of the portal venous system. This
      procedure allows the selective transplantation of the insulin-producing cell population
      avoiding open surgery as well as the transplantation of the duodenum and the exocrine
      pancreas and their related morbidity.

      The initial efforts with ICT had only modest results. The immunosuppression regimen was
      similar to the one used in solid organ transplantation, based on high dose steroids and
      calcineurin inhibitors - both agents with diabetogenic effects. The results improved markedly
      with the changes in the manipulations of the islets, and the change in immunosuppression thus
      avoiding the higher doses of steroids and using sirolimus, tacrolimus and daclizumab
      initiated by the investigators group at the University of Alberta in Edmonton, Canada. Their
      protocol requires in general two islet cell infusions in order to attain the critical cell
      mass necessary to achieve insulin-independency. The changes in treatment were adopted as the
      Edmonton Protocol, which is used in several transplant centers, worldwide.

      A novel approach to organ preservation uses the two-layer preservation technique. This allows
      for longer travel time for the eventual shipment of the pancreas to an islet cell processing
      facility remotely located from the donor procurement site.

      The isolation of the islets from the donor pancreas will be performed at the Diabetes
      Research Institute in Miami, Florida, according to the standard currently used by that
      institution. The Diabetes Research Institute is a well-established center with a
      state-of-the-art islet cell isolation facility for the purpose of transplantation in humans,
      accredited and monitored by the FDA according to FDA standards.

      The focus of the research in the ICT is centered on the development of a safe and effective
      procedure that will eventually replace surgical pancreas transplantation together with an
      ideal immunosuppressive regimen that provides safe and effective prevention against
      rejection, while minimizing the adverse events associated that negatively impact transplant
      recipient's quality of life.

      This study is being conducted as a validation of the Edmonton protocol for ICT at our
      institution. Our aim is to test the efficacy of the use of the two-layer preservation
      technique for transport of the donor pancreas to the off-site processing facility and the use
      of islet cell culture in the off-site processing facility before the islet isolate is shipped
      to our center.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Achievement of Insulin Independence at 12-month Post Transplant</measure>
    <time_frame>12 months post transplant</time_frame>
    <description>To assess the number of patients who achieve insulin independence at 12-month after islet cell transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence or Absence of Hypoglycemic Unawareness</measure>
    <time_frame>12 months after transplantation</time_frame>
    <description>Number of patients who achieved absence of hypoglycemic unawareness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Hypoglycemic Episodes</measure>
    <time_frame>12 months after transplantation</time_frame>
    <description>Blood glucose &lt;70 mg/dl, number of times reported per month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Insulin Requirements in Patients Who Did Not Become Insulin Independent</measure>
    <time_frame>12 months after transplantation</time_frame>
    <description>Percentage of insulin requirement at month 12 against that at baseline in the patients who did not achieve insulin independence. The percentage less than 100% indicates that subjects reduced insulin requirements 12 months after islet transplantation when compared with those at pre-transplant, while the parentage more than 100% represents that patients needed higher amount of exogenous insulin 12 months after islet transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Islet Cell Mass Obtained After Remote Site Processing</measure>
    <time_frame>At transplantation</time_frame>
    <description>The sum of Islet mass obtained after transport using the two-layer preservation method, remote site processing and islet culture. Islet mass as defined by Islet Equivalent per kilogram recipient body weight.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Islet Cell Infusions Needed to Achieve Insulin Independence</measure>
    <time_frame>12 months after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Function</measure>
    <time_frame>12 months after transplantation</time_frame>
    <description>Glomerular filtration rate measured by sodium iothalamate I-125 injection (GLOFIL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity Related to the Immunosuppression Regimen</measure>
    <time_frame>12 months after transplantation</time_frame>
    <description>Number of participants who experienced serious adverse events related to immunosuppression regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity Related to the Islet Cell Infusion</measure>
    <time_frame>12months after transplantation</time_frame>
    <description>Number of participants who experienced serious adverse events related to islet cell infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Quality of Life of the Recipients Measured With the RAND 36-item Short Form Health Survey</measure>
    <time_frame>12 months after transplantation</time_frame>
    <description>Averaged score in subscales of 'physical functioning', 'Role limitations due to emotional problems', 'energy/fatigue', 'emotional well-being', 'social functioning', 'pain' and 'general health' in the RAND 36-item short form health survey (SF-36). Full scale range is 0-100 for all subscales with 100 as the best outcome and 0 as the worst outcome.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Islet Cell Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allogenic islet cell transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Islet cell transplantation</intervention_name>
    <description>Allogenic islet transplantation</description>
    <arm_group_label>Islet Cell Transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient has been fully informed and has signed an Institutional Review Board (IRB)
             approved informed consent form and is willing and able to follow study procedures for
             the full 2 years

          2. Patient is expected to receive an islet cell transplant (up to 3 infusions) for type I
             diabetes mellitus

               -  Type I diabetes of more than 5 years duration

               -  Age between 18 and 65

               -  Unstable diabetes mellitus control, as defined by glucose measurements above 200
                  mg/dL and/or below 80 mg/dL despite adequate medical care

               -  Hypoglycemia unawareness, as defined by episodes of loss of cognitive function

               -  Incapacitating signs and symptoms, as defined by the referring physician

               -  Poor control of HbA1c &gt; 8%

               -  Psychogenically able to comply, in the opinion of the investigator

          3. Female patients of childbearing potential must have a negative urine or serum
             pregnancy test upon hospitalization or within 7 days prior to enrollment and have
             agreed to utilize effective birth control throughout the study as well as for 6 weeks
             following study completion.

        Exclusion Criteria:

        Patients meeting any of the following criteria will be excluded from study participation.

          1. Patient has previously received or is receiving an organ or bone marrow transplant

          2. Patient has a known hypersensitivity to Tacrolimus, sirolimus, daclizumab, or CellCept

          3. Patient is pregnant or lactating

          4. Patient has participated in a blinded trial or participated in a trial involving a
             non-marketed (investigational) drug within 3 months of enrollment

          5. Patient has participated in a trial involving a marketed drug or an infusion device
             within 30 days of the start of the trial

          6. Glomerular filtration rate (GLOFIL) &lt; 60 mL/min

          7. Serum Creatinine &gt; 1.6 mg/dL consistently

          8. Body mass index &gt; 30

          9. Autoimmune thyroiditis

         10. Malignancy other than basal cell carcinoma or squamous cell carcinoma

         11. Radiographic evidence of pulmonary infection

         12. Evidence of liver disease

         13. Portal hypertension

         14. Active infections

         15. Hypercoagulable states (history of recurrent venous thrombosis, defined thrombophilia)

         16. Bleeding / coagulation disorders

         17. Basal insulin C-Peptide &gt; 0.3 ng/dL

         18. Insulin C-peptide &gt; 0.3 ng/dL during stimulation test

         19. HbA1c &gt; 12%

         20. Insulin requirement &gt; 1 IU/kg/day

         21. Seropositivity for Human immunodeficiency virus (HIV), hepatitis B virus (HBV),
             hepatitis C virus (HCV), Human T-cell leukemia virus-1 (HTLV-1)

         22. Abnormal Pap smear in the last two months, active gynecological infection

         23. Positive exercise or chemical tolerance test

         24. Steroid dependence

         25. Substance/alcohol abuse

         26. Untreated proliferating diabetic retinopathy aa) Purified protein derivative (PPD)
             conversion or positive PPD without isonicotinic acid hydrazide (INH) bb) No Primary
             care physician or primary care physician less than 6 months cc) Smoking in the last 6
             months dd) Abnormal Complete Blood Count (CBC) / Hemoglobin &lt; 12 g/dL ee)
             Macroalbuminuria &gt; 300 mg/24 hours ff) History of thyroid disease other than
             autoimmune disease gg) Untreated hyperlipidemia - Total Cholesterol (TC) &gt; 240 mg/dL,
             Triglycerides (TGC) &gt; 200 mg/dL, Low Density Lipoprotein (LDL) &gt; 140 mg/dL hh)
             Untreated hyponatremia, hypokalemia, hypercalcemia, hypocalcemia ii) Iodine contrast
             allergy jj) Prostate Specific Antigen (PSA) &gt; 4 kk) Panel Reactive Antibody (PRA) &gt;
             20% ll) Active peptic ulcer disease/gallstones/hemangioma mm) Abnormal mammogram
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marlon Levy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor Regional Transplant Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baylor Regional Transplant Institute - Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <results_first_submitted>February 11, 2013</results_first_submitted>
  <results_first_submitted_qc>May 15, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 6, 2014</results_first_posted>
  <last_update_submitted>June 9, 2017</last_update_submitted>
  <last_update_submitted_qc>June 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Hypoglycemia</keyword>
  <keyword>Hyperglycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period took place between April 2003 thru November 2005. Consent took place in the transplant clinic at Baylor University Medical Center (BUMC).</recruitment_details>
      <pre_assignment_details>Patients signed informed consent after a consultation visit with tyhe PI. Then they proceeded through the evaluation phase of the study. During this phase, some patients were excluded based off of clinical findings (i.e. lab reports or procedures that did not meet protocol standards).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Islet Cell Transplantation</title>
          <description>Patients who received islet cell transplantation. The recipients will be given islet cell preparation with more than 4000 Islet Equivalent (IE)/kg for multiple times up to 3 infusions.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Islet Cell</title>
          <description>Patients with allogeneic islet cell transplantation</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.5" spread="11.56143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Achievement of Insulin Independence at 12-month Post Transplant</title>
        <description>To assess the number of patients who achieve insulin independence at 12-month after islet cell transplantation</description>
        <time_frame>12 months post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Islet Cell</title>
            <description>Allogeneic Islet Cell Transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Achievement of Insulin Independence at 12-month Post Transplant</title>
          <description>To assess the number of patients who achieve insulin independence at 12-month after islet cell transplantation</description>
          <units>participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence or Absence of Hypoglycemic Unawareness</title>
        <description>Number of patients who achieved absence of hypoglycemic unawareness</description>
        <time_frame>12 months after transplantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Islet Cell</title>
            <description>Allogeneic Islet Cell Transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Presence or Absence of Hypoglycemic Unawareness</title>
          <description>Number of patients who achieved absence of hypoglycemic unawareness</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Hypoglycemic Episodes</title>
        <description>Blood glucose &lt;70 mg/dl, number of times reported per month</description>
        <time_frame>12 months after transplantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Islet Cell</title>
            <description>Allogeneic Islet Cell Transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Hypoglycemic Episodes</title>
          <description>Blood glucose &lt;70 mg/dl, number of times reported per month</description>
          <units>episodes per month</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Insulin Requirements in Patients Who Did Not Become Insulin Independent</title>
        <description>Percentage of insulin requirement at month 12 against that at baseline in the patients who did not achieve insulin independence. The percentage less than 100% indicates that subjects reduced insulin requirements 12 months after islet transplantation when compared with those at pre-transplant, while the parentage more than 100% represents that patients needed higher amount of exogenous insulin 12 months after islet transplantation.</description>
        <time_frame>12 months after transplantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Islet Cell</title>
            <description>Allogeneic Islet Cell Transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Insulin Requirements in Patients Who Did Not Become Insulin Independent</title>
          <description>Percentage of insulin requirement at month 12 against that at baseline in the patients who did not achieve insulin independence. The percentage less than 100% indicates that subjects reduced insulin requirements 12 months after islet transplantation when compared with those at pre-transplant, while the parentage more than 100% represents that patients needed higher amount of exogenous insulin 12 months after islet transplantation.</description>
          <units>Percent decrease compared to baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.3" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Islet Cell Mass Obtained After Remote Site Processing</title>
        <description>The sum of Islet mass obtained after transport using the two-layer preservation method, remote site processing and islet culture. Islet mass as defined by Islet Equivalent per kilogram recipient body weight.</description>
        <time_frame>At transplantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Islet Cell</title>
            <description>Allogeneic Islet Cell Transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Islet Cell Mass Obtained After Remote Site Processing</title>
          <description>The sum of Islet mass obtained after transport using the two-layer preservation method, remote site processing and islet culture. Islet mass as defined by Islet Equivalent per kilogram recipient body weight.</description>
          <units>Islet Equivalent per kilogram</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8717" spread="2243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Islet Cell Infusions Needed to Achieve Insulin Independence</title>
        <time_frame>12 months after transplantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Islet Cell</title>
            <description>Allogeneic Islet Cell Transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Islet Cell Infusions Needed to Achieve Insulin Independence</title>
          <units>number of infusion</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Function</title>
        <description>Glomerular filtration rate measured by sodium iothalamate I-125 injection (GLOFIL)</description>
        <time_frame>12 months after transplantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Islet Cell</title>
            <description>Allogeneic Islet Cell Transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Function</title>
          <description>Glomerular filtration rate measured by sodium iothalamate I-125 injection (GLOFIL)</description>
          <units>ml/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.3" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morbidity Related to the Immunosuppression Regimen</title>
        <description>Number of participants who experienced serious adverse events related to immunosuppression regimen</description>
        <time_frame>12 months after transplantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Islet Cell</title>
            <description>Allogeneic Islet Cell Transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Morbidity Related to the Immunosuppression Regimen</title>
          <description>Number of participants who experienced serious adverse events related to immunosuppression regimen</description>
          <units>participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morbidity Related to the Islet Cell Infusion</title>
        <description>Number of participants who experienced serious adverse events related to islet cell infusion</description>
        <time_frame>12months after transplantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Islet Cell</title>
            <description>Allogeneic Islet Cell Transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Morbidity Related to the Islet Cell Infusion</title>
          <description>Number of participants who experienced serious adverse events related to islet cell infusion</description>
          <units>participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Quality of Life of the Recipients Measured With the RAND 36-item Short Form Health Survey</title>
        <description>Averaged score in subscales of 'physical functioning', 'Role limitations due to emotional problems', 'energy/fatigue', 'emotional well-being', 'social functioning', 'pain' and 'general health' in the RAND 36-item short form health survey (SF-36). Full scale range is 0-100 for all subscales with 100 as the best outcome and 0 as the worst outcome.</description>
        <time_frame>12 months after transplantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Islet Cell</title>
            <description>Allogeneic Islet Cell Transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>The Quality of Life of the Recipients Measured With the RAND 36-item Short Form Health Survey</title>
          <description>Averaged score in subscales of 'physical functioning', 'Role limitations due to emotional problems', 'energy/fatigue', 'emotional well-being', 'social functioning', 'pain' and 'general health' in the RAND 36-item short form health survey (SF-36). Full scale range is 0-100 for all subscales with 100 as the best outcome and 0 as the worst outcome.</description>
          <units>Scores on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.6" spread="12.4" lower_limit="57.8" upper_limit="88.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months after transplantation</time_frame>
      <desc>The number of adverse events which was observed within 12 months after transplantation</desc>
      <group_list>
        <group group_id="E1">
          <title>Islet Cell</title>
          <description>Patients with allogeneic islet cell transplantation</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea and Vomiting</sub_title>
                <description>Patient experienced N &amp; V which the PI determined was related to the protocol stated immunosuppressive medications.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Liver Function Tests</sub_title>
                <description>Three patients had elevated liver function tests post transplant and 1 patient had gallbladder hemorrhage.</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea and vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>mouth ulcer</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Three of the four patients voluntarily withdrew from the study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Marlon Levy</name_or_title>
      <organization>Baylor University Medical Center</organization>
      <phone>214-820-2050</phone>
      <email>Marlon.Levy@baylorhealth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

